Sze-Wen Ting1,2, Yi-Cheng Chen3,2, Yu-Huei Huang4,5. 1. Department of Dermatology, Chang Gung Memorial Hospital, Linkou, No 5, Fuxing Street, Guishan District, Taoyuan, 333, Taiwan. 2. School of Medicine, Chang Gung University, Taoyuan, Taiwan. 3. Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan. 4. Department of Dermatology, Chang Gung Memorial Hospital, Linkou, No 5, Fuxing Street, Guishan District, Taoyuan, 333, Taiwan. huang3764@mail2000.com.tw. 5. School of Medicine, Chang Gung University, Taoyuan, Taiwan. huang3764@mail2000.com.tw.
Abstract
BACKGROUND AND OBJECTIVES: Ustekinumab is used to treat moderate-to-severe psoriasis by blocking the interleukin-12/23 pathway, which is also essential against intracellular pathogens. Because there is a high prevalence of hepatitis B viral infection in Taiwan, the expected risk of reactivation is higher among ustekinumab-treated patients. We performed this study to investigate the risk of hepatitis reactivation. SUBJECTS AND METHODS: Patients with psoriasis treated with ustekinumab from October 2011 to June 2016 were enrolled in a prospective cohort study. All patients were tested for hepatitis B serology and serum viral DNA at baseline. For those positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibodies (anti-HBc) testing for HBV DNA was conducted at least annually. An increase of HBV DNA > 2 log scale or emergence of HBV DNA were defined as reactivation. The primary outcome of this study was HBV reactivation. RESULTS: Ninety-three psoriasis patients receiving ustekinumab were included. The average duration of treatment and follow-up was 24 ± 12 months. There were 39 patients classified as naïve to HBV or vaccinated, and none of these patients had HBV reactivation. Among the remaining 54 patients classified as inactive HBV carriers, resolved HBV infection, or isolated anti-HBc positivity, only 3 patients experienced virologic reactivation, and none had liver failure. CONCLUSION: The study outcomes indicate that ustekinumab could be safe for psoriasis patients since none developed persistent hepatitis or acute liver failure during therapy. However, the re-appearance of plasma HBV DNA requires appropriate monitoring of HBV viral load during ustekinumab treatment.
BACKGROUND AND OBJECTIVES:Ustekinumab is used to treat moderate-to-severe psoriasis by blocking the interleukin-12/23 pathway, which is also essential against intracellular pathogens. Because there is a high prevalence of hepatitis B viral infection in Taiwan, the expected risk of reactivation is higher among ustekinumab-treated patients. We performed this study to investigate the risk of hepatitis reactivation. SUBJECTS AND METHODS: Patients with psoriasis treated with ustekinumab from October 2011 to June 2016 were enrolled in a prospective cohort study. All patients were tested for hepatitis B serology and serum viral DNA at baseline. For those positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibodies (anti-HBc) testing for HBV DNA was conducted at least annually. An increase of HBV DNA > 2 log scale or emergence of HBV DNA were defined as reactivation. The primary outcome of this study was HBV reactivation. RESULTS: Ninety-three psoriasispatients receiving ustekinumab were included. The average duration of treatment and follow-up was 24 ± 12 months. There were 39 patients classified as naïve to HBV or vaccinated, and none of these patients had HBV reactivation. Among the remaining 54 patients classified as inactive HBV carriers, resolved HBV infection, or isolated anti-HBc positivity, only 3 patients experienced virologic reactivation, and none had liver failure. CONCLUSION: The study outcomes indicate that ustekinumab could be safe for psoriasispatients since none developed persistent hepatitis or acute liver failure during therapy. However, the re-appearance of plasma HBV DNA requires appropriate monitoring of HBV viral load during ustekinumab treatment.
Authors: Kenneth B Gordon; Richard G Langley; Craig Leonardi; Darryl Toth; M Alan Menter; Sewon Kang; Michael Heffernan; Bruce Miller; Regina Hamlin; Liberata Lim; Jianhua Zhong; Rebecca Hoffman; Martin M Okun Journal: J Am Acad Dermatol Date: 2006-08-10 Impact factor: 11.527
Authors: Alice B Gottlieb; Robert Evans; Shu Li; Lisa T Dooley; Cynthia A Guzzo; Daniel Baker; Mohan Bala; Colleen W Marano; Alan Menter Journal: J Am Acad Dermatol Date: 2004-10 Impact factor: 11.527
Authors: Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich Journal: Lancet Date: 2008-05-17 Impact factor: 79.321
Authors: Craig L Leonardi; Alexa B Kimball; Kim A Papp; Newman Yeilding; Cynthia Guzzo; Yuhua Wang; Shu Li; Lisa T Dooley; Kenneth B Gordon Journal: Lancet Date: 2008-05-17 Impact factor: 79.321
Authors: Fernando Magro; Alexandre Nuzzo; Cândida Abreu; Diogo Libânio; Iago Rodriguez-Lago; Katarzyna Pawlak; Marcus Hollenbach; Willem P Brouwer; Keith Siau Journal: United European Gastroenterol J Date: 2021-06-30 Impact factor: 6.866